HDAC9 and Carcinoma, Lewis Lung: This study aimed to investigate the potential of entinostat, a class I HDAC-selective inhibitor, on RT or a combination of RT and anti-PD-1 using a syngeneic murine Lewis lung carcinoma LL/2 model.